The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System

Alsuhaibani DS, Edrees HH, Alshammari TM. Saudi pharmaceutical journal 2023; 31(7):1360-1366

ARTICLE IDENTIFIERS

DOI: 10.1016/j.jsps.2023.05.023

PMID: 37304358

PMCID: PMC10232922

JOURNAL IDENTIFIERS

LCCN: not available pISSN: 1319-0164 eISSN: 2213-7475 OCLC ID: 36185000 CONS ID: not available

US National Library of Medicine ID: 9705695

This article was identified from a query of the SafetyLit database.